Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

前列腺癌是男性中第二常见的癌症，每年有超百万男性确诊。转移性疾病的主要治疗方式是雄激素剥夺疗法（ADT），但多数患者最终会发展为 mCRPC。阿比特龙醋酸盐作为一种雄激素受体信号抑制剂（ARSIs），能不可逆地抑制细胞色素 P450 17α（CYP17），阻断雄激素合成，联合 ADT 可使血清睾酮水平降至检测不到的低水平，同时需联合皮质类固醇以抑制促肾上腺皮质激素（ACTH）升高带来的不良反应。

A new study by UC San Francisco found that prostate cancer cases are increasing in California, likely due to a change in ...

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...